These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34387088)

  • 21. Suppression of T
    Ghosh S; Lora JM
    Drug Discov Today Technol; 2016 Mar; 19():39-44. PubMed ID: 27769356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Synthesis of a Highly Selective and
    Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
    J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoiesis provides a BRD's eye view of BET protein function.
    Stonestrom AJ; Hsu SC; Werner MT; Blobel GA
    Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.
    Hirst DJ; Bamborough P; Al-Mahdi N; Angell DC; Barnett HA; Baxter A; Bit RA; Brown JA; Chung CW; Craggs PD; Davis RP; Demont EH; Ferrie A; Gordon LJ; Harada I; Ho TCT; Holyer ID; Hooper-Greenhill E; Jones KL; Lindon MJ; Lovatt C; Lugo D; Maller C; McGonagle G; Messenger C; Mitchell DJ; Pascoe DD; Patel VK; Patten C; Poole DL; Shah RR; Rioja I; Stafford KAJ; Tape D; Taylor S; Theodoulou NH; Tomlinson L; Wall ID; Wellaway CR; White G; Prinjha RK; Humphreys PG
    J Med Chem; 2024 Jun; 67(12):10464-10489. PubMed ID: 38866424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
    Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
    Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
    Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and Characterization of a Positron Emission Tomography Imaging Probe Selectively Targeting the Second Bromodomain of Bromodomain Protein BRD4.
    Bai P; Lan Y; Wang H; Liu Y; Striar R; Yuan G; Afshar S; Zagaroli JS; Tocci DR; Langan AG; Wang C
    Bioconjug Chem; 2021 Aug; 32(8):1711-1718. PubMed ID: 34139120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
    Mirguet O; Lamotte Y; Donche F; Toum J; Gellibert F; Bouillot A; Gosmini R; Nguyen VL; Delannée D; Seal J; Blandel F; Boullay AB; Boursier E; Martin S; Brusq JM; Krysa G; Riou A; Tellier R; Costaz A; Huet P; Dudit Y; Trottet L; Kirilovsky J; Nicodeme E
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2963-7. PubMed ID: 22386529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
    Fidanze SD; Liu D; Mantei RA; Hasvold LA; Pratt JK; Sheppard GS; Wang L; Holms JH; Dai Y; Aguirre A; Bogdan A; Dietrich JD; Marjanovic J; Park CH; Hutchins CW; Lin X; Bui MH; Huang X; Wilcox D; Li L; Wang R; Kovar P; Magoc TJ; Rajaraman G; Albert DH; Shen Y; Kati WM; McDaniel KF
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1804-1810. PubMed ID: 29678460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
    Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
    J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family.
    Yang Y; Chen P; Zhao L; Zhang F; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Chem; 2019 Sep; 90():103044. PubMed ID: 31220668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of the anti-inflammatory activity of novel 8-quinolinesulfonamide derivatives as TLR4/MD-2 inhibitors with efficacy in adjuvant-induced arthritis.
    Liu T; Xing S; Du J; Wang M; Han J; Li Z
    Bioorg Chem; 2021 Sep; 114():105037. PubMed ID: 34120022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.